Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for United Therapeutics Corporation (UTHR : NSDQ)

• Company Description    United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Number of Employees: 1,400

• Price / Volume Information    Yesterday's Closing Price: $587.50 Daily Weekly Monthly 20 Day Moving Average: 926,008 shares Shares Outstanding: 42.89 (millions) Market Capitalization: $25,198.46 (millions) Beta: 0.49 52 Week High: $609.35 52 Week Low: $409.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 24.41% 25.73% 12 Week 11.73% 9.00% Year To Date 20.57% 7.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1000 SPRING ST - SILVER SPRING,MD 20910 USA ph: 301-608-9292 fax: 301-608-9291 ir@unither.com http://www.unither.com

• General Corporate Information    Officers Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James C. Edgemond - Chief Financial Officer and Treasurer Paul A. Mahon - Executive Vice President; General Counsel; and Cor Christopher Causey - Director Peer Information United Therapeutics Corporation (GSAC) United Therapeutics Corporation (CASIF) United Therapeutics Corporation (ALCD.) United Therapeutics Corporation (OMNN) United Therapeutics Corporation (CGPI.) United Therapeutics Corporation (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 91307C102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 42.89 Most Recent Split Date: 9.00 (2.00:1) Beta: 0.49 Market Capitalization: $25,198.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $6.91 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $26.07 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 5.30% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: 22.54 Trailing 12 Months: 21.02 PEG Ratio: 4.26 Price Ratios Price/Book: 3.94 Price/Cash Flow: 17.81 Price / Sales: 7.99 EPS Growth vs. Year Ago Period: 13.42% vs. Previous Quarter: 24.91% Sales Growth vs. Year Ago Period: -1.92% vs. Previous Quarter: 0.23% ROE 09/30/26 - - 06/30/26 - 20.18 03/31/26 - 19.24 ROA 09/30/26 - - 06/30/26 - 17.98 03/31/26 - 17.25 Current Ratio 09/30/26 - - 06/30/26 - 5.73 03/31/26 - 4.79 Quick Ratio 09/30/26 - - 06/30/26 - 5.41 03/31/26 - 4.50 Operating Margin 09/30/26 - - 06/30/26 - 41.56 03/31/26 - 40.62 Net Margin 09/30/26 - - 06/30/26 - 41.56 03/31/26 - 40.62 Pre-Tax Margin 09/30/26 - - 06/30/26 - 49.87 03/31/26 - 50.75 Book Value 09/30/26 - - 06/30/26 - 149.22 03/31/26 - 139.02 Inventory Turnover 09/30/26 - - 06/30/26 - 2.39 03/31/26 - 2.41 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©